Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Nov 1 2014;37(11):1757-65
Some patients prefer morning administration to allow any mild nausea to resolve during the day, while others may prefer evening injection if they experience fatigue or other symptoms following administration
The safety and effectiveness of EGRIFTA WR (11.6 mg/vial formulation) has been established based on adequate and well controlled studies with EGRIFTA (1 mg/vial formulation), as well as a demonstration of comparable bioavailability between the 1.28 mg EGRIFTA WR dose (11.6 mg/vial formulation) and the 2 mg EGRIFTA dose (1 mg/vial formulation) [see Clinical Pharmacology (12.3)]
Importantly, it has been reported that the pentadecapeptide affects signaling of one of the crucial angiogenic factors, the vascular endothelial growth factor and its receptors (VEGFR)
In a 2-year trial involving patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with semaglutide 0.5 and 1 mg once weekly injections (3%) compared to placebo (1.8%)
US$ 29.57
US$ 22.84
US$ 25.92
US$ 20.48